Drug overdose deaths are at unprecedented levels in the United States. 1 Prescription opioids have been the most common drug involved in overdose deaths, but heroin and synthetic opioids (primarily illicit fentanyl) are increasingly implicated in overdoses. 2 In addition, synthetic opioids are increasingly found in illicit drug supplies of heroin, cocaine, methamphetamine, and counterfeit pills. 3 To date, the involvement of synthetic opioids in overdose deaths involving other drugs is not well characterized, limiting the ability to implement effective clinical and public health strategies. Using 2010-2016 mortality data, we describe recent trends for synthetic opioid involvement in drug overdose deaths. . Among drug overdose deaths, opioid-related deaths were those assigned ICD-10 codes T40.0 to T40.4, and T40.6. Prescription opioids were defined as natural/semi-synthetic opioids (T40.2) and methadone (T40.3); heroin (T40.1); synthetic opioids excluding methadone (T40.4); cocaine (T40.5); psychostimulants with abuse potential (T43.6); benzodiazepines (T42.4); antidepressants (T43.0-T43.2); antipsychotics and neuroleptics (T43.3-T43.5); barbiturates (T42.3); other illicit drugs (cannabis, lysergic acid diethylamide [LSD], and other hallucinogens, T40.7-T40.9); and alcohol (T51.0). We calculated the number of synthetic opioid-involved overdose deaths by year for 2010 through 2016 overall and the number and percentage of overdose deaths involving the psychotherapeutic and illicit drugs listed above in which synthetic opioids were involved in the death. In addition, we calculated the number and percentage of synthetic opioid overdose deaths in 2016 also involving any drug or alcohol and psychotherapeutics, illicit drugs, or alcohol. The Joinpoint Regression Program (National Cancer Institute), version 4.3.1.0, was used to examine statistically significant changes in trends (eg, P trend) from 2010 through 2016. Because National Vital Statistics System data are not drawn from a sample but represent the full census of deaths in the United States, standard errors and CIs for estimates were not included. A 2-sided P value less than .05 was considered statistically significant.
1 Prescription opioids have been the most common drug involved in overdose deaths, but heroin and synthetic opioids (primarily illicit fentanyl) are increasingly implicated in overdoses.
2 In addition, synthetic opioids are increasingly found in illicit drug supplies of heroin, cocaine, methamphetamine, and counterfeit pills. 3 To date, the involvement of synthetic opioids in overdose deaths involving other drugs is not well characterized, limiting the ability to implement effective clinical and public health strategies. Using 2010-2016 mortality data, we describe recent trends for synthetic opioid involvement in drug overdose deaths. , and other hallucinogens, T40.7-T40.9); and alcohol (T51.0). We calculated the number of synthetic opioid-involved overdose deaths by year for 2010 through 2016 overall and the number and percentage of overdose deaths involving the psychotherapeutic and illicit drugs listed above in which synthetic opioids were involved in the death. In addition, we calculated the number and percentage of synthetic opioid overdose deaths in 2016 also involving any drug or alcohol and psychotherapeutics, illicit drugs, or alcohol. The Joinpoint Regression Program (National Cancer Institute), version 4.3.1.0, was used to examine statistically significant changes in trends (eg, P trend) from 2010 through 2016. Because National Vital Statistics System data are not drawn from a sample but represent the full census of deaths in the United States, standard errors and CIs for estimates were not included. A 2-sided P value less than .05 was considered statistically significant.
Results | Among the 42 249 opioid-related overdose deaths in 2016, 19 413 involved synthetic opioids, 17 087 involved prescription opioids, and 15 469 involved heroin. Synthetic opioid involvement in these deaths increased significantly from 3007 (14.3% of opioid-related deaths) in 2010 to 19 413 (45.9%) in 2016 (P for trend <.01). Significant increases in synthetic opioid involvement in overdose deaths involving prescription opioids, heroin, and all other illicit or psychotherapeutic drugs were found from 2010 through 2016 (Table) .
Among synthetic opioid-related overdose deaths in 2016, 79.7% involved another drug or alcohol. The most common coinvolved substances were another opioid (47.9%), heroin (29.8%), cocaine (21.6%), prescription opioids (20.9%), benzodiazepines (17.0%), alcohol (11.1%), psychostimulants (5.4%), and antidepressants (5.2%) ( Figure) .
Discussion | In 2016, synthetic opioids eclipsed prescription opioids as the most common drug involved in overdose deaths in the United States. These findings underscore the rapidly increasing involvement of synthetic opioids in the drug overdose epidemic and in recent increases in overdose deaths involving illicit and psychotherapeutic drugs. This analysis was limited by the 15% to 25% of death certificates in which the type of drug(s) involved in the overdose was not specified, an omission due to lack of toxicological testing or failure to record test results on death certificates. Thus, the numbers reported are likely underestimates. In addition, some of the increase in synthetic opioid involvement found in this study may be related to increased testing and detection of synthetic opioids.
Lack of awareness about synthetic opioid potency, variability, availability, and increasing adulteration of the illicit drug supply poses substantial risks to individual and public health. 4, 5 Widespread public health messaging is needed, and clinicians, first responders, and lay persons likely to respond to an overdose should be trained on synthetic opioid risks and equipped with multiple doses of naloxone. These efforts should be part of a comprehensive strategy to reduce the illicit supply of opioids and expand access to medication-assisted treatment for opioid addiction. For the synthetic opioids category, the columns for "deaths involving synthetic opioids" represent deaths in which synthetic opioids were the only drug involved in the overdose.
Letters

COMMENT & RESPONSE
Cervical Pessary and Spontaneous Preterm Birth
To the Editor Dr Saccone and colleagues 1 conducted a randomized clinical trial on the effect of a cervical pessary in women with singleton pregnancies and short cervical length and found that a pessary compared with no pessary resulted in a lower rate of spontaneous preterm birth. The authors achieved exactly their trial registry-planned sample size of 300, with 100% follow-up and 100% adherence to treatment allocation in both groups. The adherence seems implausible, as my patients commonly request removal for discomfort or other reasons. In addition, exactly equal numbers of 150 women were randomized to each group. Women were "randomized by a web-based system … implemented by use of a central telephone number." According to the protocol, http://www .randomization.com was used, and this can produce exactly 150 per group if 25 randomized blocks each of size 2, 4, and 6 are entered. But "randomization was stratified by cervical length (≤20 mm or >20 mm to ≤25 mm)," so separate random sequences must have been created for each stratum. For example, in the stratum with cervical length more than 20 mm (Table 1 in the article), 17 women (150 minus 133) were recruited in the pessary group and 25 (150 minus 125) in the control group. This imbalance of 8 is impossible with balanced blocks of 2, 4, and 6. At most, the imbalance would be 3, if recruitment ended halfway through a block of 6 with 3 same allocations in a row.
There is also a problem with the Kaplan-Meier analysis presented in the article's Figure 2A (all delivery types) and Figure 2B (spontaneous delivery only). The curves differ, albeit not by much, but the numbers at risk at each gestation were identical. Could one of the sets of numbers at risk be wrong? In Reply As Dr Thornton suggests, one of the strengths of our trial was the 100% follow-up and the 100% adherence to the treatment allocation in the pessary group. These high rates were obtained because all women included in the trial delivered at the study institution. Moreover, included women were extensively informed by the research staff about the risk of preterm delivery. We strongly believe that all women would keep a cervical pessary if clinicians clearly explained to them that the benefits of having a healthy full-term infant outweigh the risk of having discomfort. Indeed, almost all women in the pessary group experienced some adverse effects (86.7% had vaginal discharge and 3.3% had pelvic discomfort) but none of them had the device removed. Effective physician-patient communication is a central clinical function in building a therapeutic relationship. 
